Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Yangco, B. G.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

BRIEF COMMUNICATION

Discontinuation of Chemoprophylaxis against Pneumocystis carinii Pneumonia in Patients with HIV Infection

right arrow Bienvenido G. Yangco, MD, MPH; Jennifer C. Von Bargen, BS; Anne C. Moorman, BSN, MPH; Scott D. Holmberg, MD, MPH, for the HIV Outpatient Study (HOPS) Investigators*

1 February 2000 | Volume 132 Issue 3 | Pages 201-205

Background: HIV-infected patients with sustained immunologic improvement from antiretroviral therapy may be able to discontinue chemoprophylaxis against Pneumocystis carinii pneumonia (PCP).

Objective: To compare PCP incidence in HIV-infected patients who had sustained CD4+ lymphocyte counts greater than 200 cells/mm3 and who either discontinued or continued PCP prophylaxis.

Design: Nonrandomized prospective cohort study.

Setting: 10 HIV clinics in eight U.S. cities.

Patients: 146 patients had follow-up visits for a mean of 18.2 months after discontinuation of PCP prophylaxis, and 345 patients who continued PCP prophylaxis had follow-up visits for a mean of 14.0 months.

Measurements: Incidence of PCP.

Results: Patients who discontinued PCP prophylaxis had higher maximum and minimum CD4+ cell counts and lower viral loads than patients who continued PCP prophylaxis. Pneumocystis carinii pneumonia did not develop in either group (upper 95% exact binomial confidence limit of incidence for those who discontinued PCP prophylaxis, 2.3/100 person-years).

Conclusions: Discontinuation of PCP chemoprophylaxis may be appropriate for some HIV-infected ambulatory patients.

*For members of the HIV Outpatient Study Investigators, see Appendix.

Author and Article Information
space

From the Infectious Disease Research Institute, Tampa, Florida; and Centers for Disease Control and Prevention, Atlanta, Georgia.

Acknowledgments: The authors thank Kathy Wood, APACHE Medical Systems, Inc., for continued technical support of this project and Jon Kaplan and Alan Greenberg of the Centers for Disease Control and Prevention for helpful advice and editorial suggestions.

Grant Support: By a Cooperative Agreement (U64/CCU5096889) between the Centers for Disease Control and Prevention and the Health Research Network of APACHE Medical Systems.

Requests for Single Reprints: Bienvenido G. Yangco, MD, MPH, 4728 North Habana Avenue, Suite 303, Tampa, FL 33614.

Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.

Current Author Addresses: Dr. Yangco: 4728 North Habana Avenue, Suite 303, Tampa, FL 33614.

Ms. Moorman, Ms. Von Bargen, and Dr. Holmberg: CDC/DHAP, Mailstop E-45, Atlanta, GA 30333.

Author Contributions: Conception and design: B.G. Yangco, A.C. Moorman, S.D. Holmberg.

Analysis and interpretation of the data: J.C. Von Bargen, A.C. Moorman, S.D. Holmberg.

Drafting of the article: B.G. Yangco, S.D. Holmberg.

Critical revision of the article for important intellectual content: J.C. Von Bargen, S.D. Holmberg.

Final approval of the article: S.D. Holmberg.

Provision of study materials or patients: B.G. Yangco.

Statistical expertise: J.C. Von Bargen.

Obtaining of funding: S.D. Holmberg.

Administrative, technical, or logistic support: A.C. Moorman, S.D. Holmberg.

Collection and assembly of data: B.G. Yangco, A.C. Moorman.


Related articles in Annals:

Summaries for Patients
Discontinuing Medications Used To Prevent Pneumocystis carinii Pneumonia in Patients with HIV Infection
Annals 2000 132: 201. [Full Text]  



This article has been cited by other articles:


Home page
Arch Intern MedHome page
S. J. Goldie, J. E. Kaplan, E. Losina, M. C. Weinstein, A. D. Paltiel, G. R. Seage III, D. E. Craven, A. D. Kimmel, H. Zhang, C. J. Cohen, et al.
Prophylaxis for Human Immunodeficiency Virus-Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines
Arch Intern Med, April 22, 2002; 162(8): 921 - 928.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. M. Lederman and H. Valdez
Immune Restoration With Antiretroviral Therapies: Implications for Clinical Management
JAMA, July 12, 2000; 284(2): 223 - 228.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. A. Kovacs and H. Masur
Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection
N. Engl. J. Med., May 11, 2000; 342(19): 1416 - 1429.
[Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2000 by the American College of Physicians.